AXL and rheumatoid arthritis: The assumption of a defective expression of Axl in patients with RA was elegantly demonstrated in 2017 by Kurowska-Stolarska et al., who showed that CD1c+ DCs isolated from patients with RA have constitutively high levels of miR-34a and, subsequently, inhibited Axl expression in comparison with healthy donors [55].